T cell testing should be standardised & scalable. The Immuno-T Laboratory Test Kit enables this.
- Quantifiable Results
- Absolute Units
- Objective Readout
Contains all reagents required to perform T cell testing in any lab.
- Lyophilised Antigens
- Complete ELISA Kit
- Clear Instructions
Developed for immunology research applications.
- Vaccine development
- Public health studies
- T cell research
Principle of the Immuno-T™ test
The Immuno-T™ test is used to determine whether an individual possesses T cell reactivity to the selected test antigens. This T cell response may have arisen through exposure, prior infection, vaccination, or antigen cross-reactivity. For example, prior scientific evidence indicates that the T cell response measured by the Immuno-T test can identify an individual’s risk of testing positive for COVID-19 in the 6 months following the test1.
T cells can be reactivated in vitro by exposure to antigens causing the release of Interferon-gamma (IFN-ꙋ) into the blood plasma, which can be measured in a sample of plasma via Enzyme Linked Immunosorbent Assay (ELISA). Reactive T cells can be identified in fresh venous blood collected into lithium- or sodium-heparin blood collection tubes.
Simple Process
COVID-19 Immuno-T™
Drawing on our expertise in measuring adaptive immune responses to viruses, ImmunoServ has created the COVID-19 Immuno-T™ test, a simple scalable whole blood-based assay for measuring T cell responses to SARS-CoV-2.
The test has shown that the magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response is an important correlate of protection, accurately determining COVID-19 immunity1. It has been used in multiple research studies to measure SARS-CoV-2-specific T cell responses in healthy donors2, cancer patients2, people with multiple sclerosis3 and other immune compromised patients4.
Read more about Our Impact during the COVID-19 pandemic here.
Ordering
The COVID-19 Immuno-T™ Laboratory Test Kit is available in two sizes: 20 test kit (1-plate) and 100 test kit (5-plate).
Wild Type - 20 test kit (1-plate)
- Sufficient reagents for 20 tests and 1 ELISA.
- Test Antigens: SARS-CoV-2; Wild Type (Wuhan); S, M, N peptides
Wild Type - 100 test kit (5-plate)
- Sufficient reagents for 100 tests and 5 ELISAs.
- Test Antigens: SARS-CoV-2; Wild Type (Wuhan); S, M, N peptides
Omicron - 20 test kit (1-plate)
- Sufficient reagents for 20 tests and 1 ELISA.
- Test Antigens: SARS-CoV-2; Omicron BA.1; S, M, N peptides
Omicron - 100 test kit (5-plate)
- Sufficient reagents for 100 tests and 5 ELISAs.
- Test Antigens: SARS-CoV-2; Omicron BA.1; S, M, N peptides
Developed and manufactured in collaboration with ImmunitasBio.
Resources and Downloads
To learn more about measuring T cell responses using Immuno-T™ kits download our White Paper written by Dr Martin Scurr, CSO. This free article includes evidence on the benefits of using whole blood versus PBMCs, and how to scale up T cell testing using capillary blood samples.
The Immuno-T™ Laboratory Test Kit Instructions For Use provide detailed instructions of how to perform the Immuno-T test in any laboratory. It includes a list of what is included in the kits and what is required but not included.
Coming Soon
Flu Immuno-T™ Laboratory Test Kit
ImmunoServ's scientists are developing an influenza (flu) T cell test kit. This kit will contain all reagents necessary for measuring T cell immune responses to the latest WHO recommended composition of influenza virus vaccine strains.
Please contact us for further details and advanced purchasing.
Custom Kit Development
The Immuno-T™ assay is a flexible platform which allows T cell tests to be developed for many diseases. We are able to offer custom kits covering a range of antigens and read outs. Our T cell experts can provide support in the development and validation of bespoke Immuno-T kits for your research needs.
Examples antigens include:
- Zika virus
- Chikungunya virus
- Cancer antigens
- Auto-antigens
Example read outs include:
- IL-2
- IL-10
- IL-4
- TNFα
References
1. Scurr MJ et al. (2022). Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature Communications.
2. Scurr MJ et al. (2021). Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers. Immunology.
3. Tallantyre E, Vickaryous N, et al. (2021). COVID‐19 Vaccine Response in People with Multiple Sclerosis. Annals of Neurology.
4. Ponsford M, et al. (2021). Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report. Journal of Clinical Immunology.